RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced that an overview of the Company’s metalloenzyme chemistry and biology technology will be presented at the American Chemical Society (ACS) National Meeting, to be held from August 16-20, 2015, in Boston, MA. The presentation will highlight the technology’s broad applicability to metalloenzyme targets across multiple therapeutic areas and its ability to deliver highly potent and selective compounds. William Hoekstra, Ph.D., Viamet’s Vice President of Medicinal Chemistry, will present, “Design and Optimization of Potent, Selective CYP51 Inhibitors.”
Metalloenzymes are distinguished from other enzymes in that they contain a metal atom, commonly iron or zinc, at the core of the metalloenzyme active site. The metal in these enzymes has frequently been a target for pharmaceutical intervention, and many marketed drugs act by inhibiting metalloenzymes. Viamet’s approach builds upon this rich history with a proprietary chemistry and biology technology that enables the rational design of compounds which display greater potency and selectivity than currently marketed agents.
“This invitation to present an overview of our proprietary technology at the ACS National Meeting, a premier event in the chemistry space, highlights the strength and potential of our approach,” commented Robert Schotzinger, M.D., Ph.D., and CEO of Viamet. “Our expertise in metalloenzyme chemistry and biology has resulted in multiple promising drug candidates, including VT-1161, our Phase 2b oral therapy for the treatment of onychomycosis and recurrent vulvovaginal candidiasis, and three late-stage preclinical programs for life-threatening invasive fungal infections. We are also developing preclinical programs in oncology and orphan diseases and we believe our technology will continue to generate potential new therapies that address significant unmet medical needs.”
About Viamet (www.viamet.com)
Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior safety and efficacy profiles compared to currently marketed drugs.
This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet’s business and VT-1161, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.